Patient-derived Xenograft Model Market Size & Growth Forecast 2026–2035, By Segments (Tumor Type, Model Type, End Use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growoth Outlook
Patient-derived Xenograft Model Market size was more than USD 311.66 Million in 2025 and is set to grow at a 9.7% CAGR between 2026 and 2035, exceeding USD 786.59 Million by 2035. The industry revenue for 2026 is assessed at USD 338.03 million.
Get more details on this report
Request Free Sample ReportPatient-derived Xenograft Model Market Intelligence Snapshot
Regional Market Dynamics
- North America held a 47.28% share in 2025, supported by oncology research strength, translational model adoption, and strong biopharma and CRO integration.
- Asia Pacific is expected to grow at a 10.96% CAGR, fueled by expanding biopharmaceutical development, cancer research activity, and advanced preclinical testing adoption.
Segment Momentum
- Breast Cancer held a 33.6% share in 2025, supported by extensive translational oncology research requiring reliable PDX models to evaluate tumor heterogeneity, biomarkers, and therapy responses across established disease subtypes.
- Rat models are gaining momentum because they enable more detailed biological assessment, expanded sampling, and greater procedural flexibility for research designs requiring broader physiological observation than mice models.
Market Expansion Drivers
- PDX models improving tumor biology accuracy for more reliable oncology drug testing.
- Increasing CRO and CDMO outsourcing expanding preclinical research model adoption globally.
- AI-driven biomarker stratification enhancing precision oncology research and model utilization.
Leading Market Participants
Global Market Forecast Snapshot
Market Outlook
Key companies in the patient-derived xenograft model market include Charles River Laboratories International, Inc. (United States), The Jackson Laboratory (United States), Crown Bioscience Inc. (United States), WuXi AppTec Co., Ltd. (China), Oncodesign Services SAS (France), Inotiv, Inc. (United States), Xentech SAS (France), Hera BioLabs, Inc. (United States), Altogen Labs (United States), Abnova Corporation (Taiwan).Regional and Segment Outlook
North AmericaMarket Growth Drivers and Industry Trends
Closer replication of human tumor heterogeneity, microenvironment characteristics, and treatment response patterns is reshaping purchasing decisions in the patient-derived xenograft model market. Drug developers use PDX platforms when conventional in vitro systems or standard animal models fail to generate data that is credible enough for candidate selection, especially in oncology programs where small biological differences can determine trial outcomes. This stronger biological fidelity is driving demand for the patient-derived xenograft model market by increasing the role of PDX studies in lead prioritization, efficacy testing, and translational research workflows, particularly where sponsors want preclinical evidence that better reflects clinical behavior before committing to costly downstream development.
Increasing CRO and CDMO outsourcing expanding preclinical research model adoption globally
As biopharma companies externalize more oncology development work, contract research and manufacturing partners are becoming key channels through which PDX services are sourced, standardized, and scaled. Many sponsors prefer outsourcing because establishing patient-derived model capabilities internally requires specialized animal facilities, tumor engraftment expertise, and access to curated tumor banks, all of which are more efficiently aggregated by CROs and CDMOs. This operating shift is aiding market expansion in the patient-derived xenograft model market by widening access among smaller innovators, shortening project initiation timelines, and embedding PDX studies more routinely into outsourced preclinical packages offered across major research hubs.
AI-driven biomarker stratification enhancing precision oncology research and model utilization
AI-based analysis of genomic, transcriptomic, and treatment-response data is making it easier to match specific PDX models to defined patient subgroups and drug mechanisms, which changes how researchers select and use model portfolios. Instead of relying on broad tumor category screening, developers can prioritize models with biomarker signatures that are more relevant to targeted therapies and combination regimens, improving study design efficiency and translational relevance. This is supporting market development in the patient-derived xenograft model market because model utilization increasingly depends not only on access to tumor specimens but also on the ability to computationally identify the most informative PDX cohorts for precision oncology programs.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| PDX models improving tumor biology accuracy for more reliable oncology drug testing | 2.40% | High | North America, Europe | High | Mid Term |
| Increasing CRO and CDMO outsourcing expanding preclinical research model adoption globally | 2.00% | Moderate | North America, Asia Pacific | High | Near Term |
| AI-driven biomarker stratification enhancing precision oncology research and model utilization | 1.80% | High | North America, Asia Pacific | Medium | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America held a 47.28% share of the patient-derived xenograft model market in 2025, bolstered by its established oncology research ecosystem, strong use of translational models in drug discovery, and close integration between biopharma companies, academic cancer centers, and contract research organizations. The region’s leadership is reinforced by routine adoption of patient-derived models in preclinical screening and biomarker-focused studies, where sponsors prioritize platforms that better reflect tumor heterogeneity and treatment response. High research intensity and a mature outsourcing environment also keep demand concentrated in North America, as developers move candidate therapies through more selective and data-driven preclinical pipelines.
Asia Pacific is projected to expand at a 10.96% CAGR over the forecast period, with growth in the patient-derived xenograft model market being impelled by rising cancer research activity, expanding biopharmaceutical development, and broader adoption of advanced preclinical testing capabilities. The region is seeing stronger demand from companies seeking cost-effective and scalable research support, while research institutions and service providers continue building practical expertise in handling patient tumor samples and in vivo model generation. As local drug development programs become more sophisticated and precision oncology work gains traction, adoption is accelerating in ways that directly increase regional use of these models in translational and therapeutic evaluation workflows.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Translational Oncology PlatformsGermany is strengthening patient-derived xenograft model capabilities through close collaboration between cancer research institutes and biotechnology companies. Organizations in Germany are focusing on reproducible preclinical models that support biomarker discovery and therapeutic validation.
France 🇫🇷
Academic Clinical IntegrationFrance is reinforcing patient-derived xenograft model development through partnerships between academic cancer centers and biomedical researchers. French organizations are focusing on clinically relevant models that facilitate translational research and support evaluation of innovative oncology therapies.
Italy 🇮🇹
Specialized Cancer ModelingItaly is expanding specialized patient-derived xenograft model capabilities within academic and clinical oncology research programs. Institutions in Italy are prioritizing disease-specific tumor repositories that improve preclinical investigation and strengthen collaborative therapeutic development.
Japan 🇯🇵
Precision Oncology ResearchJapan is expanding the application of patient-derived xenograft models to support individualized cancer research and next-generation drug development. Japanese institutions are emphasizing clinically relevant tumor models that enhance understanding of treatment response across diverse patient populations.
South Korea 🇰🇷
Biobank-Enabled ResearchSouth Korea is integrating patient-derived xenograft models with expanding biobanking infrastructure and translational oncology initiatives. Companies and research centers in South Korea are improving access to clinically representative tumor samples for more effective preclinical drug assessment.
United States 🇺🇸
Oncology Model InnovationThe U.S. continues to expand patient-derived xenograft model adoption across oncology research and precision medicine programs. Research organizations in the U.S. are prioritizing high-quality tumor model collections and translational studies that improve preclinical evaluation of targeted therapies.
Segment Leadership and Growth Trends
Patient-derived Xenograft Model Market Share (%), Tumor Type, 2025
Go beyond the chart, access full insights & data tables
Request Free Sample ReportBreast Cancer held a 33.6% share of the patient-derived xenograft model market in 2025, making it the leading tumor type segment. This position is sustained by the high and ongoing use of breast cancer PDX models in translational oncology research, where investigators need clinically relevant platforms to study tumor heterogeneity, biomarker behavior, and therapy response across well-characterized disease subtypes. The segment’s leadership in the patient-derived xenograft model market also reflects the depth of established research activity and the consistent demand for dependable preclinical models that can support drug evaluation in a complex and widely studied cancer setting.
Lung Cancer is emerging as the fastest-growing segment in the patient-derived xenograft model market as research priorities increasingly center on aggressive disease biology, treatment resistance, and the need for more predictive preclinical validation. Growth is being reinforced through the practical value of lung cancer PDX models in capturing patient-specific tumor characteristics that are often difficult to reproduce in conventional systems. Compared with alternative tumor types, lung cancer is gaining stronger momentum because model fidelity is especially important in therapeutic decision research where disease variability and response complexity directly affect development pathways.
Model Type Segment Analysis: Mice Model (Largest Segment) vs Rat Model (Fastest-Growing Segment)
By 2025, Mice Model accounted for the largest share of the patient-derived xenograft model market. Its leadership is rooted in the long-established use of mice as the standard host system for tumor engraftment studies, where researchers rely on familiar handling protocols, broad experimental acceptance, and efficient integration into routine oncology workflows. In the patient-derived xenograft model market, this segment continues to lead because operational consistency and established research infrastructure make mice models the most practical choice for sustained preclinical use.
Rat Model is the fastest-growing segment in the patient-derived xenograft model market, encouraged by increasing demand for model systems that can support more detailed biological assessment in settings where scale and physiological observation matter. The segment is gaining momentum relative to mice-based alternatives because researchers are turning to rat models when study requirements call for expanded sampling, monitoring, or procedural flexibility that better fits certain experimental designs. This practical research advantage is the key factor accelerating adoption.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Tumor Type | Lung Cancer, Pancreatic Cancer, Prostate Cancer, Breast Cancer, Others | Breast Cancer | Lung Cancer |
| Model Type | Mice Model, Rat Model | Mice Model | Rat Model |
| End Use | Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, CRO's and CDMO's | CRO's and CDMO's | Pharmaceutical and Biopharmaceutical Companies |
Competitive Landscape and Market Positioning
1. Charles River Laboratories International Inc. (United States)
2. The Jackson Laboratory (United States)
3. Crown Bioscience Inc. (United States)
4. WuXi AppTec Co. Ltd. (China)
5. Oncodesign Services SAS (France)
6. Inotiv Inc. (United States)
7. Xentech SAS (France)
8. Hera BioLabs Inc. (United States)
9. Altogen Labs (United States)
10. Abnova Corporation (Taiwan)
The patient-derived xenograft model market is benefiting from rising demand for highly accurate preclinical testing methods in oncology research. Collaborative research initiatives are supporting the development of advanced tumor modeling systems capable of improving drug response analysis and personalized medicine applications. Increased focus on translational research is also encouraging broader adoption of biologically relevant testing platforms across pharmaceutical development pipelines.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| No companies available. | |||||||
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| BioLineRx | Jan-25 | BioLineRx reported preclinical data demonstrating potent anti-tumor activity of GLIX1 in glioblastoma using multiple patient-derived xenograft (PDX) models. These findings, utilized alongside clinical trial development, underscore the ongoing reliance on PDX systems to validate therapeutic efficacy and optimize oncology treatment pipelines before and during early-phase human trials. |
| Altogen Labs | Aug-24 | Altogen Labs validated 10 new lung cancer xenograft models for preclinical use. This expansion of the company’s service offering provides pharmaceutical and biotechnology partners with specialized in vivo platforms to evaluate the efficacy of novel therapeutics, addressing critical research needs in the diagnosis and targeted treatment of primary lung carcinoma. |
| Crown Bioscience | May-24 | Crown Bioscience entered a five-year global collaboration with Shanghai Model Organisms Center (SMOC) to integrate over 17,000 genetically engineered mouse models into its existing portfolio. This strategic alliance significantly enhances Crown’s translational model capabilities, standardizes its global supply chain, and accelerates research partnerships in immuno-oncology and personalized cancer drug discovery. |
| Crown Bioscience | May-23 | Crown Bioscience inaugurated a new research facility in Singapore to expand its global capacity for preclinical and translational oncology drug discovery. The site serves as a regional hub for biotech and pharmaceutical clients, providing increased access to specialized model services and supporting the growing demand for high-quality PDX-based drug development workflows in the Asia-Pacific market. |
| Crown Bioscience | Sep-22 | Crown Bioscience and MBL launched integrated drug discovery services in Japan. This joint venture leverages the specialized capabilities of both JSR Life Sciences subsidiaries, providing local access to advanced organoid and high-content imaging technologies alongside Crown’s established library of approximately 3,000 PDX models, facilitating comprehensive translational research within the Japanese pharmaceutical sector. |
Explore This Report
Click a section of the wheel — or its numbered marker — to preview the custom segmentation, custom table of contents, or related reports available for this market.
Patient-derived Xenograft Model Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| No segment data available. | |
Patient-derived Xenograft Model Market — report.custom
| Custom Chapter | Custom Details | ||
|---|---|---|---|
| No custom TOC data available. | |||
Need a different cut of the data?
Request Custom ResearchHow much revenue does the patient-derived xenograft model market generate?
What is the projected value of the patient-derived xenograft model industry by 2035?
How are patient-derived xenograft models influencing oncology drug development strategies?
What operational trends are expanding adoption of patient-derived xenograft models?
Why is breast cancer the largest tumor type segment in the patient-derived xenograft model market?
Why are rat models the fastest-growing model type in the patient-derived xenograft model market?
What makes North America a dominant region in the patient-derived xenograft model market?
Why is Asia Pacific gaining momentum in patient-derived xenograft model adoption?
What are the prominent companies operating in the patient-derived xenograft model landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source Category | Research Sources | Purpose |
|---|---|---|
| Government Publications | Government agencies, statistical departments, regulatory bodies | Industry statistics, regulatory insights, and policy analysis |
| Company Disclosures | Annual reports, investor presentations, financial filings | Company performance, business strategy, and market positioning |
| Trade Associations | Industry associations and professional organizations | Industry developments, standards, and market perspectives |
| Technical Literature | Research papers, technical publications, academic journals | Technology developments and technical validation |
| Patent Analysis | Patent databases and intellectual property publications | Innovation trends, technology activity, and competitive research |
| Industry Databases | Established research databases and market intelligence resources | Market benchmarking, historical data, and industry analysis |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization